Desq Long
Sign in

Company

Maze Therapeutics, Inc.

MAZE · CIK 0001842295

SEC FORM 4
$254,501.98

Maze Therapeutics, Inc. (MAZE)

Sale of 9,705 shares at $26.2238 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code S

Traded Sep 4, 2026 · Disclosed Sep 8, 2026

Source: SEC Form 4 · 0002050172-26-000036 · filed 2026-09-08 · View filing →

SEC FORM 4
$293,482.05

Maze Therapeutics, Inc. (MAZE)

Sale of 11,282 shares at $26.0133 per share.

Reporting Person Coloma Jason V · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0001676170-26-000022 · filed 2026-09-04 · View filing →

SEC FORM 4
$3,324.96

Maze Therapeutics, Inc. (MAZE)

Sale of 129 shares at $25.7749 per share.

Reporting Person Coloma Jason V · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0001676170-26-000022 · filed 2026-09-04 · View filing →

SEC FORM 4
$51,766.47

Maze Therapeutics, Inc. (MAZE)

Sale of 1,990 shares at $26.0133 per share.

Reporting Person Courtney Phillips · Officer Title GC and Corp. Secretary · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0001782758-26-000008 · filed 2026-09-04 · View filing →

SEC FORM 4
$567.16

Maze Therapeutics, Inc. (MAZE)

Sale of 22 shares at $25.7800 per share.

Reporting Person Courtney Phillips · Officer Title GC and Corp. Secretary · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0001782758-26-000008 · filed 2026-09-04 · View filing →

SEC FORM 4
$83,424.65

Maze Therapeutics, Inc. (MAZE)

Sale of 3,207 shares at $26.0133 per share.

Reporting Person Dandekar Atul · Officer Title CSBO · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0002050167-26-000027 · filed 2026-09-04 · View filing →

SEC FORM 4
$929.16

Maze Therapeutics, Inc. (MAZE)

Sale of 36 shares at $25.8100 per share.

Reporting Person Dandekar Atul · Officer Title CSBO · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0002050167-26-000027 · filed 2026-09-04 · View filing →

SEC FORM 4
$133,448.23

Maze Therapeutics, Inc. (MAZE)

Sale of 5,130 shares at $26.0133 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0002050172-26-000034 · filed 2026-09-04 · View filing →

SEC FORM 4
$1,521.02

Maze Therapeutics, Inc. (MAZE)

Sale of 59 shares at $25.7800 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0002050172-26-000034 · filed 2026-09-04 · View filing →

SEC FORM 4
$259,856.35

Maze Therapeutics, Inc. (MAZE)

Sale of 9,852 shares at $26.3760 per share.

Reporting Person Coloma Jason V · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0001676170-26-000022 · filed 2026-09-04 · View filing →

SEC FORM 4
$37,291.51

Maze Therapeutics, Inc. (MAZE)

Sale of 1,375 shares at $27.1211 per share.

Reporting Person Coloma Jason V · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0001676170-26-000022 · filed 2026-09-04 · View filing →

SEC FORM 4
$45,841.49

Maze Therapeutics, Inc. (MAZE)

Sale of 1,738 shares at $26.3760 per share.

Reporting Person Courtney Phillips · Officer Title GC and Corp. Secretary · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0001782758-26-000008 · filed 2026-09-04 · View filing →

SEC FORM 4
$6,590.43

Maze Therapeutics, Inc. (MAZE)

Sale of 243 shares at $27.1211 per share.

Reporting Person Courtney Phillips · Officer Title GC and Corp. Secretary · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0001782758-26-000008 · filed 2026-09-04 · View filing →

SEC FORM 4
$73,852.80

Maze Therapeutics, Inc. (MAZE)

Sale of 2,800 shares at $26.3760 per share.

Reporting Person Dandekar Atul · Officer Title CSBO · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0002050167-26-000027 · filed 2026-09-04 · View filing →

SEC FORM 4
$10,604.35

Maze Therapeutics, Inc. (MAZE)

Sale of 391 shares at $27.1211 per share.

Reporting Person Dandekar Atul · Officer Title CSBO · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0002050167-26-000027 · filed 2026-09-04 · View filing →

SEC FORM 4
$118,190.86

Maze Therapeutics, Inc. (MAZE)

Sale of 4,481 shares at $26.3760 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0002050172-26-000034 · filed 2026-09-04 · View filing →

SEC FORM 4
$16,950.69

Maze Therapeutics, Inc. (MAZE)

Sale of 625 shares at $27.1211 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 4, 2026

Source: SEC Form 4 · 0002050172-26-000034 · filed 2026-09-04 · View filing →

SEC FORM 4
$68,214.05

Maze Therapeutics, Inc. (MAZE)

Sale of 2,593 shares at $26.307 per share.

Reporting Person Coloma Jason V · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001676170-26-000020 · filed 2026-09-03 · View filing →

SEC FORM 4
$838,784.74

Maze Therapeutics, Inc. (MAZE)

Sale of 31,908 shares at $26.2876 per share.

Reporting Person Coloma Jason V · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001676170-26-000020 · filed 2026-09-03 · View filing →

SEC FORM 4
$0.00

Maze Therapeutics, Inc. (MAZE)

Acquisition (code M) of 50,000 shares at $0 per share.

Reporting Person Coloma Jason V · Officer Title Chief Executive Officer · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001676170-26-000020 · filed 2026-09-03 · View filing →

SEC FORM 4
$0.00

Maze Therapeutics, Inc. (MAZE)

Acquisition (code M) of 11,000 shares at $0 per share.

Reporting Person Courtney Phillips · Officer Title GC and Corp. Secretary · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001782758-26-000006 · filed 2026-09-03 · View filing →

SEC FORM 4
$0.00

Maze Therapeutics, Inc. (MAZE)

Acquisition (code M) of 12,500 shares at $0 per share.

Reporting Person Dandekar Atul · Officer Title CSBO · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0002050167-26-000025 · filed 2026-09-03 · View filing →

SEC FORM 4
$168,189.22

Maze Therapeutics, Inc. (MAZE)

Acquisition (code M) of 16,141 shares at $10.42 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0002050172-26-000032 · filed 2026-09-03 · View filing →

SEC FORM 4
$425,512.27

Maze Therapeutics, Inc. (MAZE)

Sale of 16,141 shares at $26.3622 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0002050172-26-000032 · filed 2026-09-03 · View filing →

SEC FORM 4
$0.00

Maze Therapeutics, Inc. (MAZE)

Acquisition (code M) of 20,000 shares at $0 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0002050172-26-000032 · filed 2026-09-03 · View filing →

SEC FORM 4
$78,150.00

Maze Therapeutics, Inc. (MAZE)

Acquisition (code M) of 7,500 shares at $10.42 per share.

Reporting Person Dandekar Atul · Officer Title CSBO · Transaction Code M

Traded Aug 28, 2026 · Disclosed Aug 31, 2026

Source: SEC Form 4 · 0002050167-26-000023 · filed 2026-08-31 · View filing →

SEC FORM 4
$206,823.75

Maze Therapeutics, Inc. (MAZE)

Sale of 7,500 shares at $27.5765 per share.

Reporting Person Dandekar Atul · Officer Title CSBO · Transaction Code S

Traded Aug 28, 2026 · Disclosed Aug 31, 2026

Source: SEC Form 4 · 0002050167-26-000023 · filed 2026-08-31 · View filing →

SEC FORM 4
$168,199.64

Maze Therapeutics, Inc. (MAZE)

Acquisition (code M) of 16,142 shares at $10.42 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code M

Traded Aug 13, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002050172-26-000028 · filed 2026-08-14 · View filing →

SEC FORM 4
$445,620.89

Maze Therapeutics, Inc. (MAZE)

Sale of 16,142 shares at $27.6063 per share.

Reporting Person Bernstein Harold · Officer Title President, R&D & CMO · Transaction Code S

Traded Aug 13, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002050172-26-000028 · filed 2026-08-14 · View filing →